Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

DISEASE CHARACTERISTICS:

* At high risk for ovarian cancer and meets criteria for 1 of the following:

  * Family history of at least 2 ovarian\*\* or breast cancers\* among the patient and first- or second-degree relatives in the same lineage

    * Multiple primary cancers in the same person may fulfill this requirement
  * Ashkenazi Jewish ethnicity AND 1 first-degree or 2 second-degree relatives with breast\* or ovarian\*\* cancer
  * Ashkenazi Jewish ethnicity AND had prior breast cancer\*
  * BRCA1/BRCA2 mutation probability \> 20% by BRCAPRO
  * Positive for BRCA1 or BRCA2 mutation
  * First- or second-degree relative with a BRCA1/BRCA2 mutation NOTE: \*At least 1 breast cancer must be premenopausal (diagnosed at age 50 or under if menopausal status unknown); ductal carcinoma in situ qualifies as breast cancer

NOTE: \*\*In relatives, only ovarian epithelial cancer, fallopian tube cancer, and primary papillary serous cancer qualifies as ovarian cancer

* No prior or concurrent ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum

  * No clinical evidence of ovarian cancer by physical examination, CA 125 evaluation, and pelvic ultrasound

PATIENT CHARACTERISTICS:

Age

* 19 and over

Performance status

* GOG 0-1

Life expectancy

* Not specified

Hematopoietic

* WBC \> 3,000/mm\^3
* Granulocyte count \> 1,500/mm\^3
* Platelet count \> 100,000/mm\^3
* No hemophilia or other bleeding disorder
* No serious anemia

Hepatic

* Transaminases normal
* Bilirubin normal

Renal

* Creatinine clearance \> 80 mL/min OR
* Creatinine \< 2.0 mg/dL

Pulmonary

* No emphysema

Other

* Not pregnant or nursing
* No psychiatric or psychological condition that would preclude giving informed consent
* No concurrent untreated malignancy except nonmelanoma skin cancer
* No other medical condition that would preclude blood draws (e.g., chronic infectious disease)

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* More than 3 months since prior adjuvant chemotherapy

Endocrine therapy

* Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed

Radiotherapy

* More than 3 months since prior adjuvant radiotherapy

Surgery

* More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)
* No prior oophorectomy

Other

* More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy
* No concurrent participation in other ovarian cancer early detection clinical trials